With this report you’ll gain understanding of new EU pharmacovigilance rules, from preapproval through the life of a drug, plus insight into compliance in a new era. Specifically you’ll discover:

  • How to deal with the PRAC
  • How to tailor a PRAC-ready pharmacovigilance system, including finding and appointing a new “qualified person” (QP) to oversee pharmacovigilance
  • How to adapt to broad new definitions of adverse drug reactions, including monitoring of off-label uses and misuses
  • How to prepare for safety label warning changes to accompany products whenever a regulator requests additional safety monitoring
  • And much more!

To receive a FREE copy of the FDAnews management report, Understanding EU Drug Safety Reporting, simply provide us with the information requested below.

You'll get immediate access to the report when you click the "submit button."